| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $19,212,314 ) (Continued on the next page) |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01DE035829 | Pro-CanDy (Probiotic-Loaded Hydrogels for the Prevention and Management of Oral Candidiasis and Dysbiosis) | 000 | 1 | NIH | 6/1/2026 | $363,375 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R21CA299243 | Image-guided adaptable CAR T cell therapy for solid tumors | 000 | 1 | NIH | 6/11/2026 | $415,257 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | F32AR085954 | Mechanisms Regulating Tendon Fibrosis and Adhesion Formation | 000 | 1 | NIH | 6/10/2026 | $76,780 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI190307 | Deciphering the activation mechanisms and immune functions of GSDMC | 000 | 1 | NIH | 3/27/2026 | $2,469,932 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI195499 | The epigenetic regulation of alloimmune stem-like CD4+ T cells | 000 | 1 | NIH | 2/3/2026 | $491,663 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA268340 | XBP1 Inhibition and STING activation for the treatment of cancer | 000 | 5 | NIH | 4/17/2026 | $574,484 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI134637 | The LiaFSR system and antimicrobial peptide resistance in enterococci | 000 | 7 | NIH | 5/20/2026 | $806,820 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL163535 | Human Atherogenesis with Underlying Dysfunctional HDL-Free Cholesterol | 001 | 4 | NIH | 4/23/2026 | $22,444 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL163535 | Human Atherogenesis with Underlying Dysfunctional HDL-Free Cholesterol | 000 | 4 | NIH | 3/11/2026 | $710,747 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R21AI190338 | Mechanisms of Resistance and Clinical Outcomes of non-Carbapenemase Producing Carbapenem-Resistant Klebsiella pneumoniae Infections | 001 | 2 | NIH | 4/6/2026 | $24,747 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R21AI190338 | Mechanisms of Resistance and Clinical Outcomes of non-Carbapenemase Producing Carbapenem-Resistant Klebsiella pneumoniae Infections | 000 | 2 | NIH | 3/26/2026 | $164,100 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS140292 | DeepStroke+: An Advanced Mobile AI Diagnostic Tool for Fast and Precise Detection of Acute Strokes in Mobile Stroke Units, Emergency Rooms, and Telestroke Triage | 001 | 2 | NIH | 2/23/2026 | $59,440 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS140292 | DeepStroke+: An Advanced Mobile AI Diagnostic Tool for Fast and Precise Detection of Acute Strokes in Mobile Stroke Units, Emergency Rooms, and Telestroke Triage | 000 | 2 | NIH | 1/19/2026 | $534,966 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA285209 | Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors | 001 | 3 | NIH | 4/16/2026 | $48,987 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA285209 | Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors | 000 | 3 | NIH | 1/12/2026 | $440,870 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R61CA278458 | A multiplexed high-throughput platform to report pharmacologic alteration of cancer stem cell membrane potential and cell cycle state | 000 | 3 | NIH | 4/27/2026 | $221,817 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | K23AI185174 | Pathogen and patient determinants of Candida gut colonization in critically ill patients | 000 | 3 | NIH | 6/5/2026 | $194,036 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | T32AI179595 | Antimicrobial Resistance Training Program in the Texas Medical Center (AMR-TPT) | 000 | 3 | NIH | 4/21/2026 | $331,510 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA285203 | Exploring the role and potential of anti-viral drugs to sensitize cancer cells to chemotherapy | 000 | 3 | NIH | 5/18/2026 | $472,355 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA288884 | Functional roles of mTOR in tumor persistence | 000 | 3 | NIH | 3/19/2026 | $401,087 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL158703 | Mechanisms driving cardiac dysfunction in Autosomal Dominant Polycystic Kidney Disease | 000 | 5 | NIH | 4/7/2026 | $403,750 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA280746 | Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesis | 001 | 3 | NIH | 4/16/2026 | $65,879 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA280746 | Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesis | 000 | 3 | NIH | 1/27/2026 | $592,923 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL168277 | Cardiac Autonomic Activation In Atrial Fibrillation Triggers And Substrate | 001 | 4 | NIH | 4/23/2026 | $24,089 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL168277 | Cardiac Autonomic Activation In Atrial Fibrillation Triggers And Substrate | 000 | 4 | NIH | 3/9/2026 | $762,842 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI167659 | Long-acting multi prevention implant for 2-year contraception and HIV PrEP | 000 | 4 | NIH | 4/17/2026 | $798,886 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL174587 | Advancing Endovascular PAD Treatment: Overcoming Critical Knowledge Gaps with MRI-histology | 000 | 3 | NIH | 5/12/2026 | $704,707 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI176558 | Regulation of Cell Death in HIV Reservoirs | 000 | 4 | NIH | 2/17/2026 | $593,795 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01DK133610 | Vascularized NICHE with local immunosuppression for cell replacement for Type 1 diabetes | 000 | 5 | NIH | 6/10/2026 | $753,808 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | U01CA268813 | A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC) | 001 | 4 | NIH | 4/16/2026 | $61,143 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | U01CA268813 | A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC) | 000 | 4 | NIH | 1/16/2026 | $305,910 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA269835 | Mechanisms of STING in malignant progression and therapy of CLL. | 001 | 4 | NIH | 4/16/2026 | $49,214 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA269835 | Mechanisms of STING in malignant progression and therapy of CLL. | 000 | 4 | NIH | 2/11/2026 | $442,928 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA163910 | Targeting ER stress response in B-cell chronic lymphocytic leukemia | 000 | 13 | NIH | 5/7/2026 | $403,750 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA288403 | Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy | 000 | 3 | NIH | 5/5/2026 | $589,341 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01DK134340 | A randomized, sham-controlled clinical trial evaluating individualized neuromodulation of cortical regions involved in neurogenic overactive bladder in Multiple Sclerosis | 000 | 4 | NIH | 12/17/2025 | $338,159 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA288613 | Advancing Thyroid Cancer Diagnostics with AI-enhanced Multimodal Optical Histopathology | 001 | 2 | NIH | 4/16/2026 | $48,806 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA288613 | Advancing Thyroid Cancer Diagnostics with AI-enhanced Multimodal Optical Histopathology | 000 | 2 | NIH | 2/2/2026 | $439,250 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL177797 | Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis | 001 | 2 | NIH | 3/25/2026 | $20,681 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL177797 | Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis | 000 | 2 | NIH | 2/12/2026 | $654,870 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AG080925 | Proteomics based mapping of cardiac extracellular matrix to define sex and age-dependent changes. | 000 | 5 | NIH | 4/8/2026 | $621,761 |
| | 2026 | 2026 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R21AI182870 | Novel translational strategies to combat group B streptococcus infections | 000 | 2 | NIH | 11/26/2025 | $201,875 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI179616 | Modulation of chromatin dynamics to promote transplant survival | 000 | 3 | NIH | 12/29/2025 | $628,171 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA278911 | Induction of autosis to overcome resistance in adoptive cell therapy for solid tumors | 000 | 4 | NIH | 4/17/2026 | $569,100 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | K08AI193408 | Antibiotics-associated microbiota and functional changes in immune-mediated enterocolitis. | 000 | 1 | NIH | 6/1/2026 | $184,030 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R56EY036406 | Mitochondrial factories for AMD therapy | 000 | 1 | NIH | 4/28/2026 | $1,029,472 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI080779 | Modulation of innate immune cells to create transplant tolerance | 000 | 14 | NIH | 5/26/2026 | $484,500 |
| | 2026 | 2025 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | K76AG088424 | Virtual Reality-Based Cognitive Stimulation Games for Enhancing Attention and Preventing Delirium in Older Surgical Patients with Cognitive Impairment: A Randomized Controlled Pilot Trial | 000 | 1 | NIH | 5/8/2026 | $0 |
| | 2026 | 2025 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS121405 | S100A4 mediated immune suppression in GBM | 000 | 5 | NIH | 12/11/2025 | $0 |
|
